(SDGR) Schrodinger - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 986m USD | Total Return: -29.9% in 12m

Simulation Software, Molecular Modeling, Drug Discovery, Materials Science
Total Rating 21
Safety 30
Buy Signal -0.24
Health Information Services
Industry Rotation: +9.7
Market Cap: 986M
Avg Turnover: 16.3M
Risk 3d forecast
Volatility75.0%
VaR 5th Pctl12.0%
VaR vs Median-2.67%
Reward TTM
Sharpe Ratio-0.47
Rel. Str. IBD24.4
Rel. Str. Peer Group50
Character TTM
Beta1.323
Beta Downside1.178
Hurst Exponent0.510
Drawdowns 3y
Max DD80.01%
CAGR/Max DD-0.31
CAGR/Mean DD-0.44
EPS (Earnings per Share) EPS (Earnings per Share) of SDGR over the last years for every Quarter: "2021-06": -0.32, "2021-09": -0.38, "2021-12": -0.43, "2022-03": -0.27, "2022-06": -0.17, "2022-09": -0.5, "2022-12": -0.38, "2023-03": -0.23, "2023-06": -0.6, "2023-09": -0.7, "2023-12": -0.41, "2024-03": -0.76, "2024-06": -0.74, "2024-09": -0.87, "2024-12": -0.24, "2025-03": -0.64, "2025-06": -0.65, "2025-09": -0.57, "2025-12": -0.1802, "2026-03": -0.62,
Last SUE: -0.35
Qual. Beats: 0
Revenue Revenue of SDGR over the last years for every Quarter: 2021-06: 29.784, 2021-09: 29.85, 2021-12: 46.17, 2022-03: 48.663, 2022-06: 38.469, 2022-09: 36.98, 2022-12: 56.843, 2023-03: 64.782, 2023-06: 35.189, 2023-09: 42.569, 2023-12: 74.126, 2024-03: 36.598, 2024-06: 47.334, 2024-09: 35.29, 2024-12: 88.317, 2025-03: 59.551, 2025-06: 54.759, 2025-09: 54.324, 2025-12: 87.235, 2026-03: 58.587,
Rev. CAGR: 12.00%
Rev. Trend: 86.2%
Last SUE: 2.20
Qual. Beats: 1

Warnings

Interest Coverage Ratio -2.8 is critical

Altman Z'' -4.36 < 1.0 - financial distress zone

Overextended 3d

Tailwinds

No distinct edge detected

Description: SDGR Schrodinger

Schrödinger, Inc. operates a physics-based computational platform designed to accelerate molecular discovery for drug development and materials science. The company utilizes a dual-segment business model: the Software segment provides licensed tools to external researchers, while the Drug Discovery segment manages a pipeline of internal and collaborative preclinical and clinical programs.

Operating within the Health Care Technology sector, Schrödinger utilizes predictive modeling to reduce the time and cost associated with traditional laboratory synthesis. This computational approach allows for the screening of billions of molecules before physical testing begins. The company maintains strategic partnerships with major pharmaceutical entities, such as Novartis, to co-develop specific therapeutic candidates.

Investors can further examine valuation metrics and analyst sentiment for SDGR on ValueRay. Schrödinger is headquartered in New York and serves a global client base across the life sciences and industrial materials markets.

Headlines to Watch Out For
  • Software revenue growth depends on R&D spending within pharmaceutical and biotech sectors
  • Success of internal clinical pipeline programs drives valuation and milestone payment potential
  • Licensing agreements and research collaborations provide critical non-dilutive capital and validation
  • High operational costs and R&D expenditures impact path toward sustained profitability
  • Computational platform adoption rates among materials science and life sciences industries influence scale
Piotroski VR-10 (Strict) 2.0
Net Income: -103.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.23 > 0.02 and ΔFCF/TA -26.37 > 1.0
NWC/Revenue: 115.5% < 20% (prev 175.9%; Δ -60.42% < -1%)
CFO/TA -0.23 > 3% & CFO -145.0m > Net Income -103.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.74 > 1.5 & < 3
Outstanding Shares: last quarter (74.0m) vs 12m ago 1.27% < -2%
Gross Margin: 55.33% > 18% (prev 0.63%; Δ 5.47k% > 0.5%)
Asset Turnover: 37.02% > 50% (prev 31.02%; Δ 6.00% > 0%)
Interest Coverage Ratio: -2.76 > 6 (EBITDA TTM -158.9m / Interest Expense TTM 59.6m)
Altman Z'' -4.36
A: 0.46 (Total Current Assets 464.0m - Total Current Liabilities 169.5m) / Total Assets 634.2m
B: -1.09 (Retained Earnings -688.8m / Total Assets 634.2m)
C: -0.24 (EBIT TTM -164.8m / Avg Total Assets 688.6m)
D: -2.15 (Book Value of Equity -688.2m / Total Liabilities 320.6m)
Altman-Z'' = -4.36 = D
Beneish M -2.87
DSRI: 0.53 (Receivables 27.3m/46.3m, Revenue 254.9m/230.5m)
GMI: 1.13 (GM 55.33% / 62.61%)
AQI: 1.47 (AQ_t 0.08 / AQ_t-1 0.05)
SGI: 1.11 (Revenue 254.9m / 230.5m)
TATA: 0.07 (NI -103.5m - CFO -145.0m) / TA 634.2m)
Beneish M = -2.87 (Cap -4..+1) = A
What is the price of SDGR shares?

As of June 01, 2026, the stock is trading at USD 15.20 with a total of 2,296,620 shares traded.
Over the past week, the price has changed by +14.89%, over one month by +27.09%, over three months by +25.10% and over the past year by -29.92%.

Is SDGR a buy, sell or hold?

Schrodinger has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SDGR.

  • StrongBuy: 6
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SDGR price?
Analysts Target Price 20.9 37.4%
Schrodinger (SDGR) - Fundamental Data Overview as of 01 June 2026
Market Cap USD = 985.6m (985.6m USD * 1.0 USD.USD)
P/S = 3.8987
P/B = 3.1695
Revenue TTM = 254.9m USD
EBIT TTM = -164.8m USD
EBITDA TTM = -158.9m USD
Long Term Debt = 90.9m USD (estimated: total debt 107.0m - short term 16.0m)
Short Term Debt = 16.0m USD (from shortTermDebt, last quarter)
Debt = 107.0m USD (from shortLongTermDebtTotal, last quarter) (leases 107.0m already included)
Net Debt = -292.0m USD (calculated: Debt 107.0m - CCE 399.0m)
Enterprise Value = 693.6m USD (985.6m + Debt 107.0m - CCE 399.0m)
Interest Coverage Ratio = -2.76 (Ebit TTM -164.8m / Interest Expense TTM 59.6m)
EV/FCF = -4.68x (Enterprise Value 693.6m / FCF TTM -148.4m)
FCF Yield = -21.39% (FCF TTM -148.4m / Enterprise Value 693.6m)
FCF Margin = -58.20% (FCF TTM -148.4m / Revenue TTM 254.9m)
Net Margin = -40.60% (Net Income TTM -103.5m / Revenue TTM 254.9m)
Gross Margin = 55.33% ((Revenue TTM 254.9m - Cost of Revenue TTM 113.9m) / Revenue TTM)
Gross Margin QoQ = 50.43% (prev 65.68%)
Tobins Q-Ratio = 1.09 (Enterprise Value 693.6m / Total Assets 634.2m)
 Interest Expense / Debt = 55.74% (Interest Expense 59.6m / Debt 107.0m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -130.2m (EBIT -164.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.74 (Total Current Assets 464.0m / Total Current Liabilities 169.5m)
Debt / Equity = 0.34 (Debt 107.0m / totalStockholderEquity, last quarter 313.5m)
 Debt / EBITDA = 1.84 (negative EBITDA) (Net Debt -292.0m / EBITDA -158.9m)
 Debt / FCF = 1.97 (negative FCF - burning cash) (Net Debt -292.0m / FCF TTM -148.4m)
 Total Stockholder Equity = 335.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.03% (Net Income -103.5m / Total Assets 634.2m)
RoE = -10.10% (Net Income TTM -103.5m / Total Stockholder Equity 1.02b)
RoCE = -14.78% (EBIT -164.8m / Capital Employed (Equity 1.02b + L.T.Debt 90.9m))
 RoIC = -44.37% (negative operating profit) (NOPAT -130.2m / Invested Capital 293.5m)
 WACC = 9.60% (E(985.6m)/V(1.09b) * Re(10.64%) + (debt cost/tax rate unavailable))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 1.13%
 [DCF] Fair Price = unknown (Cash Flow -148.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.35 | # QB: 0
Revenue Correlation: 86.19 | Revenue CAGR: 12.00% | SUE: 2.20 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.60 | Chg30d=-1.68% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.61 | Chg30d=+0.81% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-2.23 | Chg30d=-10.42% | Revisions=-20% | GrowthEPS=-10.1% | GrowthRev=-8.3%
EPS next Year (2027-12-31): EPS=-1.56 | Chg30d=-13.41% | Revisions=-20% | GrowthEPS=+29.7% | GrowthRev=+12.8%
[Analyst] Revisions Ratio: -20%